Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fenebrutinib in Relapsing Multiple Sclerosis
NCT05119569Phase 2Active, not recruiting
- Sponsor
- Roche
- Start
- Mar 2022
- Primary completion
- Mar 2023
- Countries
- 6
01
Overview
A Phase 2 trial of fenebrutinib in multiple sclerosis (MS), sponsored by Roche. Started Mar 2022; status: active, not recruiting.
02
Drugs
fenebrutinib
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT05119569.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05119569.